An international collaboration of researchers, sponsored by GSK and working on behalf of the ANCHOR-1 and ANCHOR-2 trial ...

Opens in a new tab or window SAN DIEGO -- Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials showed. Twice-yearly injections ...

But the flip side is also true: By making a few small changes to your routine, it’s possible to ease the symptoms of nasal polyps, says Tran Bao Locke, MD, an otolaryngologist and assistant ...

What you may think are allergies or a cold, could be the sign of nasal polyps. Nasal polyps are non-cancerous growths that line the nasal passages and sinuses. They are soft, painless, and hang ...

Asthma and antibiotic use may predict nasal polyp recurrence after endoscopic sinus surgery Date: February 4, 2025 Source: University of Eastern Finland Summary: The probability of revision sinus ...

Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) mainly to itself since June 2019, but GlaxoSmithKline’s Nucala is ...

The asthma medication reduces congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in a ...

Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy and ...

Chronic sinusitis with nasal polyps (CRSwNP) accounts for 20 to 33 percent of these cases. Even after surgical treatment, the recurrence rate of CRSwNP remains high, ranging from 20 to 60 percent ...

During the follow-up, 15.9% of patients required at least one revision surgery. The probability of revision sinus surgery including the removal of nasal polyps increased if the patient had asthma ...

The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...